Key facts
- 28bio’s last known valuation is $83.7M (Nov 2024).
- It has raised $24.0M; the latest was Later Stage VC ($6.5M) in Jan 2026.
- Notable investors include US National Science Foundation, United States Department of War, Acadian Capital Group, Benson Capital Partners, Great Stuff Ventures — 16 tracked in total.
- Status: Privately Held (backing).
Investors
16+- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for 28bio
- ·The full record, as it builds
Funding rounds
No funding rounds for 28bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 28bio
Developer of a brain-on-a-chip platform designed to capture neurological processes in the brain and nervous system. The company's platform utilizes tissue engineering, neural interfacing and artificial intelligence to measure clinically relevant electrophysiology data analyzed by models, enabling healthcare professionals to treat neurological diseases.
- Sector
- Healthcare
- HQ
- New Orleans, LA, United States
- Founded
- 2014
- Employees
- 19
- Website
- 28bio.com/
- Ownership
- Privately Held (backing)
28bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 28bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 28bio in its N-PORT filings yet. We sweep new filings monthly.